• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

RedHill Biopharma - Articles and news items

red-pill

RedHill Biopharma commences Phase II hepatocellular carcinoma study

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final…

patent-redhill-biopharma

RedHill Biopharma receives patent approval for MS drug

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

A first Phase III study with RHB-104 for the treatment of Crohn’s disease is currently ongoing, as well as a Phase IIa proof-of-concept study for the treatment of MS…

Myelin deterioration multiple sclerosis

Last patient visit in Phase IIa study with RHB-104 for multiple sclerosis

Industry news / 3 August 2016 / RedHill Biopharma Ltd.

The last patient visit has been completed in the Phase IIa study evaluating RHB-104 in patients treated for relapsing-remitting multiple sclerosis (RRMS)…

RedHill Biopharma has last patient visit in phase IIa study with RHB-104 for multiple sclerosis

RedHill Biopharma has positive results with RHB-104 for multiple sclerosis

Industry news / 1 August 2016 / RedHill Biopharma Ltd.

RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period …

yeliva

Positive results for Yeliva in Phase I advanced solid tumour study

Industry news / 4 July 2016 / Victoria White, Digital Content Producer

Yeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities…

bekinda

First patients dosed in Bekinda IBS-D trial

Industry news / 22 June 2016 / Victoria White, Digital Content Producer

The first patients have been dosed in a Phase II clinical study with RedHill Biopharma’s Bekinda 12 mg for diarrhoea-predominant irritable bowel syndrome…

RHB-105

RedHill Biopharma announces positive FDA meeting on RHB-105

Industry news / 21 April 2016 / Victoria White, Digital Content Producer

RedHill Biopharma has concluded a positive Type B Meeting with the FDA regarding the path to marketing approval of RHB-105…

bekinda

Redhill initiates Phase II study of Bekinda in IBS-D

Industry news / 12 April 2016 / Victoria White, Digital Content Producer

The randomised, double-blind Phase II clinical study is designed to evaluate the safety and efficacy of Bekinda 12 mg in patients suffering from IBS-D…

RHB-104

Encouraging top-line interim results for RHB-104 in RRMS

Industry news / 5 April 2016 / Victoria White

RedHill has announced encouraging top-line interim results from its CEASE-MS study of RHB-104 in patients with relapsing-remitting multiple sclerosis…

RHB-105

Positive results from Phase III study of RHB-105 for H. pylori infection

Industry news / 10 March 2016 / Victoria White

The ERADICATE Hp Phase III study was intended to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori bacterial infection…

rp101

RedHill Biopharma and IZI enter RP101 collaboration

Industry news / 8 February 2016 / Victoria White

The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +